U.S. Asked Not to Pressurise India to Reject Cancer Drug License

Friday, 31 October 2014, 10:37 Hrs
cmt right
Comment Right
cmt right
cmt right
Printer Print Email Email

WASHINGTON: An international organisation working for cancer-affected people has asked the Obama administration not to pressurise India to reject a compulsory license on a drug for a rare form of leukaemia, which would be a de facto endorsement of an excessive price.

In a letter to the U.S. Trade Representative (USTR), Mike Froman, Union for Affordable Cancer Treatment (UACT), opposed the policies that promote high cancer drug prices throughout the world.

UACT in its letter refers to recent reports suggesting that USTR is pressuring the Indian government to reject a compulsory license on dasatinib, a drug for a rare form of leukaemia.

The Bristol-Myers Squibb (BMS) price for dasatinib is more than $ 100 per day, which makes it unreachable for the majority of leukaemia patients in India.

U.S. government opposition to a compulsory license on dasatinib is a de facto endorsement of an excessive price, and will have predictably harsh consequences for leukaemia patients. who have developed resistance to imatinib.

The UACT letter also challenges the assumption that USTR is advancing the U.S. interests by promoting stronger monopolies of medicines.

While BMS attempts to justify high cancer drug prices on the grounds that R&D is expensive, BMS in fact spent little on the R&D for dasatinib and benefited extensively from U.S. government research subsidies, including NIH-funded research and clinical trials, and a 50 per cent tax credit on the BMS funded trials, it said.

Also Read: Nestle to Introduce Robots as Sales Clerks
Black Money Can Add Up To $35bn To Forex Kitty

Source: PTI
GST rate cut to spur Bengaluru
The realty market in India's tech hub is set to grow as lower Goods and Services Tax (GST) rate..
SpiceJet plans aggressive
Budget passenger carrier SpiceJet plans to aggressively expand its international networks to fl..
Fossil Group sells smartwatch
Global watch and accessories maker Fossil Group has announced to sell its smartphone technolog..
Ola raises Rs 400 cr for electric
Leading ride-hailing cab aggregator Ola on Friday said it raised Rs 400 crore from its early in..